Search Results

You are looking at 1 - 10 of 10 items for :

  • "somatostatin receptor ligand" x
  • Refine by Access: All content x
Clear All
Open access

Marta Araujo-Castro, Héctor Pian, Ignacio Ruz-Caracuel, Alberto Acitores Cancela, Eider Pascual-Corrales, and Víctor Rodríguez Berrocal

, tumor consistency was reported to be an important predictive factor since hard consistency could impede transsphenoidal resection, especially in macroadenomas ( 8 ). Preoperative somatostatin receptor ligands (SRLs) treatment is proven to reduce GH and

Open access

Peter Wolf, Alexandre Dormoy, Luigi Maione, Sylvie Salenave, Jacques Young, Peter Kamenický, and Philippe Chanson

pegvisomant both improve insulin sensitivity ( 6 ), glucose metabolism may improve or worsen when patients are treated with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide ( 7 , 8 , 9 , 10 ). Pasireotide is a somatostatin

Open access

Bernardo Maia, Leandro Kasuki, and Mônica R Gadelha

patients have clinical contraindications or refuse to be submitted to surgery ( 4 , 10 ). Currently, there are three classes available for the treatment of acromegaly: somatostatin receptor ligands (SRLs), dopamine agonists, and GH receptor antagonist ( 4

Open access

Hélène Lasolle, Amandine Ferriere, Alexandre Vasiljevic, Sandrine Eimer, Marie-Laure Nunes, and Antoine Tabarin

acromegaly using current criteria of biochemical ‘cure’ . European Journal of Endocrinology 2005 379 – 387 . ( ) 3 Gadelha MR Wildemberg LE Bronstein MD Gatto F Ferone D . Somatostatin receptor ligands in

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, and S Cannavò

-018-0865-7 ) 29344905 10.1007/s11102-018-0865-7 21 Cuevas-Ramos D Fleseriu M . Somatostatin receptor ligands and resistance to treatment in pituitary adenomas . Journal of Molecular Endocrinology 2014 52 R223 – R240 . ( ) 10

Open access

Sylvain Roumeau, Joannice Thevenon, Lemlih Ouchchane, Salwan Maqdasy, Marie Batisse-Lignier, Christian Duale, Nathalie Pham Dang, Philippe Caron, Igor Tauveron, and Laurent Devoize

 Pituitary surgery, n 22  Pituitary radiotherapy, n 5  Medical treatment, n 20    Dopamine agonist, n 7    Somatostatin receptor ligands, n 20    GH receptor antagonist, n 4  Never treated, n 3

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, and Albert Beckers

Ferone D . Somatostatin receptor ligands in the treatment of acromegaly . Pituitary 2017 20 100 – 108 . ( ) 10.1007/s11102-017-0791-0 28176162 17 Körner M Waser B Christ E Beck J Reubi JC . A critical

Open access

Reem Al Argan, Abdulaziz Ramadhan, Ramanakumar V Agnihotram, Jeffrey Chankowsky, and Juan Rivera

Bonneville JF . T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective . Pituitary 2017 20 116 – 120 . ( ) 16 Mukai K

Open access

T L C Wolters, C D C C van der Heijden, N van Leeuwen, B T P Hijmans-Kersten, M G Netea, J W A Smit, D H J Thijssen, A R M M Hermus, N P Riksen, and R T Netea-Maier

, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy . Journal of Clinical Endocrinology and Metabolism 2013 1040 – 1050

Open access

Rimesh Pal, Sanjay Kumar Bhadada, Awesh Singhare, Anil Bhansali, Sadishkumar Kamalanathan, Manoj Chadha, Phulrenu Chauhan, Ashwani Sood, Vandana Dhiman, Dinesh Chandra Sharma, Uma Nahar Saikia, Debajyoti Chatterjee, and Vikas Agashe

secretion by the tumor tissue. As firm evidence to our hypothesis is the fact that octreotide, a somatostatin receptor ligand, is largely ineffective in correcting the biochemical abnormalities in TIO ( 43 , 44 , 45 ). All the resected tumors ( n  = 22